OCT 11, 2017 1:30 PM PDT

Pancreatic Cancer: Challenges and Solutions

Speaker

Abstract

Pancreatic cancer is one of the “deadly” cancers, defined as those with a 5-year relative survival rate of less than 50%.  Although ranking 12th in terms of incidence, it is on track to become the second leading cause of cancer deaths by 2020.  The Pancreatic Cancer Action Network (PanCAN) set a goal of doubling survival by 2020, identified 5 specific challenges that need to be addressed, and initiated approaches to contribute to their solution.  There are not enough researchers or research, the clinical trial enrollment rate is too low, clinical trials need to be streamlined and focused, there is insufficient public awareness, and most patients are seen in the community setting where there is little experience with the disease.  Through advocating for government resources, the NCI allocation to pancreatic cancer has increased 5-fold since 1999, with several new research initiatives that resulted from the passage of the Recalcitrant Cancer Research Act in 2013.  Patient Central associates served more than 33,000 patients and families last year, providing disease and treatment information, support resources, and clinical trial searches.  The Patient Registry collects information from individual patients, learns best practices, and disseminates information on topics such as the use of pancreatic enzyme replace therapy to the scientific community.  The Know Your Tumor ® initiative has enrolled more than 1300 patients from across the US, and delivered almost 700 reports thus far detailing the results from genomic and proteomic analysis of tumor tissue with treatment options based on the molecular profiling and consideration of treatment history.  These results indicate that 25% of pancreatic cancer patients have “actionable alterations” that indicate a targeted therapy, and that the median progression-free survival of patients that utilize a report-directed targeted therapy increased by 46% over those with no highly actionable alteration.  The clinical trial landscape in pancreatic cancer has changed over the past 5 years, with a doubling of those trials that test a targeted therapy and an increase in trials for recurrent disease.  The accrual of pancreatic adenocarcinoma patients to clinical trials increased from 3.8% in 2011 to 4.2% in 2014; this is at least in part attributed to increased awareness of clinical trials through PanCAN’s Clinical Trial Finder (12% of those who access this service enroll in a clinical trial) and Know Your Tumor ® initiatives (21% of participants enroll in a clinical trial).  PanCAN is initiating Precision PromiseSM , a clinical trial and research platform with the mission of continuously and rapidly evaluating novel treatment options for pancreatic cancer.  Public awareness of the disease is raised with a volunteer presence in 90 communities throughout the US and leadership in the World Pancreatic Cancer Coalition.  A comprehensive approach to the disease, through Government Affairs, Research Grants & Clinical Initiatives, Patient Services, and Community Engagement, has resulted in significant advances on multiple fronts, helping to propel the field towards achieving the goal of doubling survival by 2020 and using that as a platform for continued and sustained improvements in the years to come.


Show Resources
You May Also Like
MAY 17, 2022 9:00 AM PDT
MAY 17, 2022 9:00 AM PDT
Date: May 17, 2022 Time: 9:00am (PDT), 12:00pm (EDT), 8:00pm (CEST) Gene therapeutics have great potential to treat many severe diseases in an unprecedented, targeted manner. The biopharmace...
JUN 21, 2022 6:00 AM PDT
JUN 21, 2022 6:00 AM PDT
Date: June 21, 2022 Time: 6:00am (PDT), 9:00am (EDT), 3:00pm (CEST) The global understanding and practice of medicine is currently undergoing a revolutionary change. This shift to precision...
JUN 28, 2022 7:00 AM PDT
JUN 28, 2022 7:00 AM PDT
Date: June 28, 2022 Time: 3:00pm (BST), 4:00pm (CET), 9:00am (CST), 7am (PST) Light-sheet microscopy is an extremely versatile imaging technique with a vast range of implementations that are...
MAR 30, 2022 6:00 AM PDT
MAR 30, 2022 6:00 AM PDT
Targeted NGS has been instrumental in helping the healthcare community deliver on the promise of precision medicine. The Ion Torrent Genexus Integrated Sequencer has enabled targeted genomic...
AUG 24, 2022 7:00 AM PDT
AUG 24, 2022 7:00 AM PDT
Date: August 24, 2022 Time: 7:00am (PDT), 10:00pm (EDT), 4:00pm (CEST) Light field microscopy was first introduced in 2006, and allows users to capture the 4D light field within the microsco...
MAR 16, 2022 8:00 AM PDT
C.E. CREDITS
MAR 16, 2022 8:00 AM PDT
Date: March 16, 2022 Time: 8:00am (PDT), 11:00am (EDT), 5:00pm (CET) Handling of potent and/or hazardous substances is commonplace in sev.....
OCT 11, 2017 1:30 PM PDT

Pancreatic Cancer: Challenges and Solutions



Show Resources
Loading Comments...
Show Resources
Attendees